Last reviewed · How we verify
Vi-DT Typhoid Conjugate Vaccine
Vi-DT Typhoid Conjugate Vaccine works by stimulating the body's immune system to produce antibodies against Salmonella Typhi.
Vi-DT Typhoid Conjugate Vaccine works by stimulating the body's immune system to produce antibodies against Salmonella Typhi. Used for Prevention of typhoid fever.
At a glance
| Generic name | Vi-DT Typhoid Conjugate Vaccine |
|---|---|
| Sponsor | PT Bio Farma |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains inactivated Salmonella Typhi bacteria, which are conjugated to a carrier protein to enhance immunogenicity. Upon administration, the vaccine induces a specific immune response, leading to the production of antibodies that can recognize and neutralize Salmonella Typhi, thereby preventing typhoid fever.
Approved indications
- Prevention of typhoid fever
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian (PHASE2, PHASE3)
- Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh (PHASE1, PHASE2)
- Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) (PHASE3)
- Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) (PHASE3)
- Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine (PHASE2)
- Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine (PHASE1)
- Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine (PHASE3)
- Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vi-DT Typhoid Conjugate Vaccine CI brief — competitive landscape report
- Vi-DT Typhoid Conjugate Vaccine updates RSS · CI watch RSS
- PT Bio Farma portfolio CI